Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.
2020
PURPOSEThe objective response rate (ORR) for single-agent anti–programmed death receptor 1 (anti–PD-1) therapy is modest in patients with metastatic or recurrent head and neck squamous cell carcino...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
19
References
61
Citations
NaN
KQI